3rd Circ. To Hear Appeal Of Cert. In Provigil Antitrust Row

The Third Circuit has agreed to hear Mylan Pharmaceuticals Inc. and Ranbaxy Pharmaceuticals Inc.'s appeal of a lower court's grant of class certification to direct buyers of narcolepsy drug Provigil who...

Already a subscriber? Click here to view full article